WO1999036398A1 - Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels - Google Patents

Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels

Info

Publication number
WO1999036398A1
WO1999036398A1 PCT/GB1999/000099 GB9900099W WO9936398A1 WO 1999036398 A1 WO1999036398 A1 WO 1999036398A1 GB 9900099 W GB9900099 W GB 9900099W WO 9936398 A1 WO9936398 A1 WO 9936398A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
benzamide
optionally substituted
substituted phenyl
Prior art date
Application number
PCT/GB1999/000099
Other languages
French (fr)
Inventor
Sandra Milutinovic
Robin George Simmonds
David Edward Tupper
Original Assignee
Eli Lilly And Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company Limited filed Critical Eli Lilly And Company Limited
Priority to AU21728/99A priority Critical patent/AU2172899A/en
Priority to EP99901722A priority patent/EP1047670A1/en
Priority to JP2000540115A priority patent/JP2002509135A/en
Priority to CA002317536A priority patent/CA2317536A1/en
Publication of WO1999036398A1 publication Critical patent/WO1999036398A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • This invention relates to novel chemical compounds and their use as pharmaceuticals .
  • the compounds of the invention have the following general formula:
  • R 2 is C ⁇ _ alkyl, C3_ ⁇ o cycloalkyl, C3_ ⁇ o cycloalkyl-
  • R3 and R ⁇ are each C]__g alkyl, C3_ ⁇ o cycloalkyl, C3_IQ
  • the nitrogen atom to which they are attached form a carbocyclic group containing 4 to 7 carbon atoms optionally substituted with one to three methyl or ethyl groups and optionally containing an oxygen atom or a further nitrogen atom, said carbocyclic group being optionally fused to an optionally substituted phenyl group; or a salt thereof.
  • the compounds of the invention have been found to be active in tests that show modulation of voltage- dependent calcium channels, and are thus indicated for use in the treatment of diseases in which such modulation is beneficial, in particular diseases of the central nervous system.
  • a C ⁇ _6 alkyl group includes
  • a substituted phenyl group is phenyl substituted with one or more, for example one to three, substituents selected from, for example C]__4 alkyl, especially methyl, C]__4 alkoxy,
  • a halo atom is preferably chlorine, bromine or fluorine.
  • a substituted phenyl group preferably has one to three substituents selected from hydroxy, C ⁇ _4
  • An optionally substituted phenyl-C]__4 alkyl group is preferably of the
  • phenyl and n is 1 to 4, but the linking chain can also be branched alkylene .
  • a C3_IQ cycloalkyl group is
  • cyclopropyl cyclobutyl, cyclopentyl or cyclohexyl and these groups may optionally be substituted by one or two C ⁇ _4 alkyl,
  • a C3_]_Q cycloalkyl- C ⁇ _4 alkyl group is one such cycloalkyl group attached
  • R-(CH2) n - where R is cycloalkyl and n is 1 to 4.
  • R ⁇ or R4 are C _ alkyl they are preferably C3_g alkyl.
  • the groups R ⁇ and R 2 , R3 and R ⁇ , and R ⁇ and R ⁇ can form a carbocyclic ring with the nitrogen to which they are attached and optionally also contain an oxygen atom or an additional nitrogen.
  • Preferred examples, including the nitrogen of the amino sulfonyl group, are pyrrolidino, piperazino, morpholino and especially 3 , 5-dimethylpiperidino .
  • a particular group of compounds of the invention is one
  • R1, R 2 , R3 and R ⁇ are each C ⁇ _6 alkyl, ⁇ - ⁇ Q cycloalkyl, C3_]_o cycloalkyl-C ⁇ __4 alkyl or optionally substituted phenyl-C ⁇ _4 alkyl, and
  • R-L is in addition hydrogen.
  • R! is hydrogen. Furthermore, R ⁇
  • R4 which can be the same or different, are
  • a further preferred group of compounds is one of
  • a further preferred group of compounds is one of
  • the compounds of the invention can contain one or more asymmetric carbon atom which gives rise to enantiomers .
  • the compounds can be prepared as racemates or can be made from enantiomeric intermediates . Both racemates and enantiomers form part of the present invention.
  • salts of the compounds of the invention can be prepared and such salts are included in the invention. They can be any of the well known acid addition salts. Acid addition salts are preferably the pharmaceutically acceptable non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example glycollic, maleic, fumaric, malic, oxalic, tartaric, citric, salicylic or o_-acetoxybenzoic acids, or organic sulfonic acids, methane sulfonic, 2-hydroxyethane sulfonic, toluene-p-sulfonic or naphthalene-2-sulfonic acids .
  • suitable acids such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids
  • organic acids such as organic carboxylic acids, for example glyco
  • salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically- acceptable, salts, or are useful for identification, characterisation or purification.
  • the invention also includes a process for producing the compounds of formula (I) above which comprises reacting a compound of the formula:
  • X is a leaving group such as, for example, halo or
  • the reaction is preferably carried out in an organic solvent such as, for example, chloroform or acetonitrile, at a temperature of from 0° C. to 100° C. such as, for example, ambient temperature.
  • organic solvent such as, for example, chloroform or acetonitrile
  • Amine reactants of the formula HNR ⁇ -R 2 are also well known and can be prepared readily by known methods.
  • R 2 is - (CH2 ) 2 NR ⁇ *R * ⁇
  • R 2 is - (CH2 ) 2 NR ⁇ *R * ⁇
  • Those in which R 2 is - (CH2 ) 2 NR ⁇ *R * ⁇ can, for example, be prepared by reductive amination, that is, by reacting the appropriate diamine with an aldehyde in reducing conditions .
  • the compounds of the invention are active in tests that indicate their utility in the treatment of diseases of the central nervous system.
  • the compounds modulate the activity of calcium channels and, in particular, they block voltage sensitive calcium channels as determined in a test based on Boot J. R. , et al . , Specificity of autoantibodies in the Lambert- Eaton Myasthenic Syndrome, Ann NY Acad. Sci . (1997), in which measurements of calcium flux using calcium sensitive dyes are made.
  • Compounds described in the following Examples were found to inhibit voltage- dependent calcium channels in cloned human cell lines expressing specific voltage-dependent calcium channels with an IC 50 of less than 10 ⁇ M.
  • the compounds of the invention are thus indicated for use in the treatment of anoxia, ischaemia, stroke and heart failure, migraine, diabetes, cognitive impairment, pain, epilepsy, traumatic head or spinal injury, AIDS related dementia and blindness, amnesia, neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases and age-related memory disorders, Down's syndrome, mood disorders, drug or alcohol addition withdrawal, nausea from chemotherapy, and carbon monoxide or cyanide poisoning.
  • the invention also includes a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier in association with the compound of the invention or a pharmaceutically acceptable salt or ester thereof .
  • the compound may be administered by various routes, for example by the oral or rectal route, topically or parenterally, for example by injection or infusion, being usually employed in the form of a pharmaceutical composition.
  • Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
  • the active ingredient will usually be mixed with a carrier, or diluted by a carrier, and/or enclosed within a carrier which may, for example, be in the form of a capsule, sachet, paper or other container.
  • the carrier when it serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
  • the composition may be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions, ointments containing, for example, up to 10% by weight of the compound, soft and hard gelatin capsules, suppositories, injection solutions and suspensions and sterile packaged powders.
  • suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl- hydrobenzoate, talc magnesium stearate and mineral oil.
  • the compositions of the injection may, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
  • each unit dosage form contains from 5 mg to 500 mg.
  • the term 'unit dosage form' refers to physically discrete units suitable as unit dosages for human subjects and animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
  • the active compound is effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.5 to 300 mg/kg, more usually in the range of from 5 to 100 mg/kg.
  • dosages per day will normally fall within the range of from 0.5 to 300 mg/kg, more usually in the range of from 5 to 100 mg/kg.
  • the amount administered will be determined by the physician in the light of the relevant circumstances including the conditions to be treated, the choice of compound to be administered and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
  • the resulting acid chloride was added to a stirred solution of p-methoxybenzylamine (1.51 g, 0.011 mole) and triethylamine (1.11 g, 0.011 mole) in dry tetrahydrofuran (25 ml) at 0-5° C. After stirring for 4 hours the reaction was poured into ice water and extracted with ethyl acetate. The solvent was washed with brine, dried and evaporated to dryness in vacuo .
  • Tablets each containing 10 mg of active ingredient are made up as follows :
  • the active ingredient, starch and cellulose are mixed thoroughly.
  • the solution of polyvinylpyrrolidone is mixed with the resultant powders and passed through a sieve.
  • the granules so produced are dried and re-passed through a sieve.
  • the sodium carboxymethyl starch and magnesium stearate are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 300 mg.
  • Capsules each containing 20 mg of active ingredient are made as follows:
  • the active ingredient, starch and magnesium stearate are passed through a sieve and filled into hard gelatine capsules in 200 mg quantities.
  • Capsules each containing 20 mg of medicament are made as follows : Active ingredient 20 mg Lactose 171 mg
  • the active ingredient, lactose, sodium lauryl sulphate and sodium starch glycollate are mixed thoroughly.
  • the blend is mixed with the magnesium stearate and filled into hard gelatine capsules in 200 mg quantities.
  • Tablets each containing 20 mg and medicaments are made as follows:
  • the active ingredient, lactose, microcrystalline cellulose, sodium starch glycollate and hydroxypropylmethylcellulose are passed through a sieve and blended together. Water is added to the blended powders to form a damp mass . The damp mass is passed through a coarse screen, dried, then re-screened. The dried granules are mixed with the magnesium stearate and compressed into tablets of 300 mg weight.

Abstract

A pharmaceutical compound of formula (I) in which the aminosulfonyl group is attached at the 3- or 4-position, and in which R1 is hydrogen, C¿1-6? Alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl or optionally substituted phenyl-C1-4 alkyl, R?2¿ is C¿1-6? alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, optionally substituted phenyl-C1-4 alkyl or -(CH2)2NR?5R6¿ where R?5 and R6¿ are each hydrogen or C¿1-6? alkyl, and R?3 and R4¿ are each C¿1-6? alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-4 alkyl, C3-6 alkenyl, optionally substituted phenyl or optionally substituted phenyl-C1-4 alkyl, or R?1 and R2, or R3 and R4, or R5 and R6¿, together with the nitrogen atom to which they are attached, form a carbocyclic group containing 4 to 7 carbon atoms optionally substituted with one to three methyl or ethyl groups and optionally containing an oxygen atom or a further nitrogen atom, said carbocyclic group being optionally fused to an optionally substituted phenyl group; or a salt thereof.

Description

AMINOSULPHONYLBENZAMIDE DERIVAΗVES AS MODULATORS OF THE ACΗVITY OF NEURONAL CALCIUM CHANNELS
This invention relates to novel chemical compounds and their use as pharmaceuticals .
It is well known that chemical compounds which modulate the activity of neuronal calcium channels are potentially useful in treating disorders of the central nervous system.
10
The compounds of the invention have the following general formula:
R1
Figure imgf000003_0001
R3
(I)
15 in which the aminosulfonyl group is attached at the 3- or 4-position, and in which R1 is hydrogen, C]__6 alkyl, C3_χo cycloalkyl, C3_IQ
cycloalkyl-Cι_4 alkyl or optionally substituted phenyl- Cχ_4 alkyl,
R2 is Cχ_ alkyl, C3_χo cycloalkyl, C3_χo cycloalkyl-
C^_4 alkyl, optionally substituted phenyl-C]__4 alkyl or
-(CH2)2NR R where R^ and R^ are each hydrogen or C]__6
alkyl , and
R3 and R^ are each C]__g alkyl, C3_χo cycloalkyl, C3_IQ
cycloalkyl-C]__4 alkyl, C3_ alkenyl, optionally
substituted phenyl or optionally substituted phenyl-Cχ_4
alkyl ,
or R1 and R2 t or R3 and R4 t or R5 and R6, together with
the nitrogen atom to which they are attached, form a carbocyclic group containing 4 to 7 carbon atoms optionally substituted with one to three methyl or ethyl groups and optionally containing an oxygen atom or a further nitrogen atom, said carbocyclic group being optionally fused to an optionally substituted phenyl group; or a salt thereof.
The compounds of the invention have been found to be active in tests that show modulation of voltage- dependent calcium channels, and are thus indicated for use in the treatment of diseases in which such modulation is beneficial, in particular diseases of the central nervous system.
In the above formula (I), a Cχ_6 alkyl group includes
methyl, ethyl, propyl, isopropyl, butyl, tert. butyl and hexyl , and is preferably methyl or ethyl. A substituted phenyl group is phenyl substituted with one or more, for example one to three, substituents selected from, for example C]__4 alkyl, especially methyl, C]__4 alkoxy,
especially methoxy and ethoxy, hydroxy, nitro, cyano, halo, especially chloro or fluoro, trihalomethyl, especially trifluoromethyl , carboxy and Cχ_4 alkoxy-
carbonyl . A halo atom is preferably chlorine, bromine or fluorine. A substituted phenyl group preferably has one to three substituents selected from hydroxy, C^_4
alkyl, halo, nitro and trifluoromethyl . An optionally substituted phenyl-C]__4 alkyl group is preferably of the
formula R-(CH2)n- where R is optionally substituted
phenyl and n is 1 to 4, but the linking chain can also be branched alkylene . A C3_IQ cycloalkyl group is
preferably, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and these groups may optionally be substituted by one or two Cχ_4 alkyl,
especially methyl, substituents. A C3_]_Q cycloalkyl- Cι_4 alkyl group is one such cycloalkyl group attached
to a C _4 alkyl, and is preferably of the formula
R-(CH2)n- where R is cycloalkyl and n is 1 to 4. When
R^ or R4 are C _ alkyl they are preferably C3_g alkyl.
The groups R^ and R2 , R3 and R^ , and R^ and R^ , can form a carbocyclic ring with the nitrogen to which they are attached and optionally also contain an oxygen atom or an additional nitrogen. Preferred examples, including the nitrogen of the amino sulfonyl group, are pyrrolidino, piperazino, morpholino and especially 3 , 5-dimethylpiperidino .
A particular group of compounds of the invention is one
of formula (I) in which R1, R2 , R3 and R4 are each C]__g
alkyl, C3_χo cycloalkyl, C3_ιo cycloalkyl-Cχ_4 alkyl or
optionally substituted phenyl-C]__4 alkyl, and R! can in
addition be hydrogen, or R1 and R2 , or R3 and R4 together with the nitrogen atom to which they are attached, form a carbocyclic group as defined above.
In a preferred group of compounds R1, R2 , R3 and R^ are each Cχ_6 alkyl, ^ -^Q cycloalkyl, C3_]_o cycloalkyl-Cι__4 alkyl or optionally substituted phenyl-Cι_4 alkyl, and
R-L is in addition hydrogen.
It is preferred that R! is hydrogen. Furthermore, R^
and R4 , which can be the same or different, are
preferably Cχ_4 alkyl. It is further preferred that R2
is optionally substituted phenyl-Cι_4 alkyl.
A further preferred group of compounds is one of
formula (I) in which R2 is - (CH ) 2NR5R6 •
A further preferred group of compounds is one of
formula (I) in which R^ or R4 is C3_g alkyl or when R^
and R^ are taken together with the nitrogen atom they form a piperidine ring which is substituted at the 3- and/or 5-positions with one or two methyl or ethyl substituents . It will be appreciated that the compounds of the invention can contain one or more asymmetric carbon atom which gives rise to enantiomers . The compounds can be prepared as racemates or can be made from enantiomeric intermediates . Both racemates and enantiomers form part of the present invention.
It will also be understood that salts of the compounds of the invention can be prepared and such salts are included in the invention. They can be any of the well known acid addition salts. Acid addition salts are preferably the pharmaceutically acceptable non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example glycollic, maleic, fumaric, malic, oxalic, tartaric, citric, salicylic or o_-acetoxybenzoic acids, or organic sulfonic acids, methane sulfonic, 2-hydroxyethane sulfonic, toluene-p-sulfonic or naphthalene-2-sulfonic acids .
In addition to pharmaceutically-acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically- acceptable, salts, or are useful for identification, characterisation or purification.
The invention also includes a process for producing the compounds of formula (I) above which comprises reacting a compound of the formula:
Figure imgf000009_0001
(II)
where X is a leaving group such as, for example, halo or
hydroxy, with an amine of the formula HNR^R2.
The reaction is preferably carried out in an organic solvent such as, for example, chloroform or acetonitrile, at a temperature of from 0° C. to 100° C. such as, for example, ambient temperature.
Intermediate compounds of formula (II) are known in the art and can be prepared readily by known methods. When an acid halide is employed (X is halo such as, for example, chloro) , the reaction is preferably carried out in the presence of a solid phase scavenger to absorb the acid liberated by the reaction. When the free acid is employed (X is hydroxy), a condensing reagent such as, for example, dimethyla inopropyl-ethylcarbodiimide can be employed.
Amine reactants of the formula HNR^-R2 are also well known and can be prepared readily by known methods.
Those in which R2 is - (CH2 ) 2NR~*R*^ can, for example, be prepared by reductive amination, that is, by reacting the appropriate diamine with an aldehyde in reducing conditions .
Alternatively, such compounds in which R is - (CH2 ) 2NR~IR^ can be prepared by alkylation of the corresponding
compound of formula (I) in which R-*- is hydrogen.
As mentioned above, the compounds of the invention are active in tests that indicate their utility in the treatment of diseases of the central nervous system. The compounds modulate the activity of calcium channels and, in particular, they block voltage sensitive calcium channels as determined in a test based on Boot J. R. , et al . , Specificity of autoantibodies in the Lambert- Eaton Myasthenic Syndrome, Ann NY Acad. Sci . (1997), in which measurements of calcium flux using calcium sensitive dyes are made. Compounds described in the following Examples were found to inhibit voltage- dependent calcium channels in cloned human cell lines expressing specific voltage-dependent calcium channels with an IC50 of less than 10 μM.
The compounds of the invention are thus indicated for use in the treatment of anoxia, ischaemia, stroke and heart failure, migraine, diabetes, cognitive impairment, pain, epilepsy, traumatic head or spinal injury, AIDS related dementia and blindness, amnesia, neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases and age-related memory disorders, Down's syndrome, mood disorders, drug or alcohol addition withdrawal, nausea from chemotherapy, and carbon monoxide or cyanide poisoning.
The invention also includes a pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier in association with the compound of the invention or a pharmaceutically acceptable salt or ester thereof . The compound may be administered by various routes, for example by the oral or rectal route, topically or parenterally, for example by injection or infusion, being usually employed in the form of a pharmaceutical composition. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, and/or enclosed within a carrier which may, for example, be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition may be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions, ointments containing, for example, up to 10% by weight of the compound, soft and hard gelatin capsules, suppositories, injection solutions and suspensions and sterile packaged powders.
Some examples of suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl- hydrobenzoate, talc magnesium stearate and mineral oil. The compositions of the injection may, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
Where the compositions are formulated in unit dosage form, it is preferred that each unit dosage form contains from 5 mg to 500 mg. The term 'unit dosage form' refers to physically discrete units suitable as unit dosages for human subjects and animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
The active compound is effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.5 to 300 mg/kg, more usually in the range of from 5 to 100 mg/kg. However, it will be understood that the amount administered will be determined by the physician in the light of the relevant circumstances including the conditions to be treated, the choice of compound to be administered and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.
The invention is illustrated by the following Preparations and Examples. EXAMPLE 1
4- (N,N-dipropylaminosulfonyl) -N-benzyl-benzamide
To 50-100 mg polyvinylpyridine was added a 25 mM solution of benzylamine in chloroform (1 ml), followed by a 37.5 mM solution of 4- (N,N-dipropylaminosulfonyl) - benzoyl chloride in chloroform (1 ml) . The mixture was shaken at room temperature for 4 hours .
Aminomethylpolystyrene (100 mg, 0.1 mmole) was added and shaking continued for a further 16.5 hours. The mixture was then filtered and the resin washed with chloroform (2 x 2 ml) . The combined filtrates were vacuum evaporated to give the required product. (TS-MS: m/z 375, [M+H]+)
The following compounds were similarly prepared (mass spectrum values are given in brackets) .
Thermospray Mass Spectrum values
4- (N,N-Dipropylaminosulfonyl) -N,N-dibenzyl-benzamide (465) - ( N , N- ■Dipropylaminosulfonyl -N-3 , 4-dimethoxybenzyl-benzamide (435) - ( N N- ■Dipropylaminosulfonyl -N-3 , 5-dimethoxybenzyl-benzamide (435 ) - N , N- ■Dipropylaminosulfonyl -N-3-methoxybenzyl-benzamide (405) - N N- •Dipropylaminosulfonyl -N-3 , 4, 5-trimethoxybenzyl-benzamide (465) - N , N- •Dipropylaminosul fonyl -N-4-chlorobenzyl-benzamide (409/410) - N N- •Dipropylaminosulfonyl -N-4-trifluoromethylbenzyl-benzamide ( 443 ) - N N Dipropylaminosul fonyl -N-4-dimethylaminobenzyl-benzamide ( 418 ) - N N -Dipropylaminosulfonyl -N-4-methylbenzyl-benzamide (389 ) - N N ■Dipropylaminosul fonyl -N-3-chlorobenzyl-benzamide (409/410) - N N -Dipropylaminosulfonyl -N-3-methylbenzyl-benzamide (389 ) - N N -Dipropylaminosulfonyl -N-3 -trifluoromethylbenzyl-benzamide (443 ) - N N -Dipropylaminosul onyl -N-3.5-difluoromethylbenzyl-benzamide ( 411 ) - N N -Dipropylaminosulfonyl -N-2, 6-dimethoxybenzyl-benzamide (435) - N N -Dipropylaminosulfonyl -N-2-methylbenzyl-benzamide (389) - N N -Dipropylaminosulfonyl -N-2-chlorobenzyl-benzamide (409/410) - N N -Dipropylaminosulfonyl -N-2-methoxybenzyl-benzamide ( 405 ) - N N -Dipropylaminosulfonyl -N-2-trifluoromethylbenzyl-benzamide ( 443 ) - N N -Dipropylaminosulfonyl -N-3 , 4-dimethylbenzyl-benzamide ( 403 ) - N N -Dipropylaminosulfony1 -N-2 , 6-dichlorobenzyl-benzamide ( 444 ) - N N -Dipropylaminosulfonyl -N-4-methoxyphenethyl-benzamide (419 ) - N N -Dipropylaminosulfonyl -N-phenethyl-benzamide (389) - N N -Dipropylaminosulfonyl -N-3-methoxyphenethyl-benzamide (419 ) - N N -Dipropylaminosulfonyl -N-4-nitrophenethyl-benzamide (434) - N N -Dipropylaminosulfonyl -N-2-phenylpropyl-benzamide (403 ) - N N -Dipropylaminosulfonyl -N-4-chlorophenethyl-benzamide ( 423 /424 ) - N N -Dipropylaminosulfonyl -N-4-methylphenethyl-benzamide (403 ) - N N -Dipropylaminosulfonyl -N-2-methoxyphenethyl-benzamide ( 419 ) - (N N -Dipropylaminosulfonyl -N-2-chlorophenethyl-benzamide (423/424) - (N N -Dipropylaminosulfonyl -N-3 -trifluoromethylphenethyl-benzamide (457 " - (N N -Dipropylaminosulfonyl -N-hexyl-benzamide (369) - (N N -Dipropylaminosulfonyl -N-2-methylbutyl-benzamide (355) 4- (4-N,N-Dipropylaminosulfonyl) benzoylmorpholine (355)
2- (4-N,N-Dipropylaminosulfonyl) benzoyl-6 , 7-dimethoxy-tetra- hydroisoquinoline (461)
4- (N,N-Dipropylaminosulfonyl -N-3-methoxypropyl-benzamide (357) 4- (N,N-Dipropylaminosulfonyl -N-2-methylpropyl-benzamide (355) 4- (N,N-Dipropylaminosulfonyl -N-cyclohexylmethyl-benzamide (381) 4- (N,N-Dipropylaminosulfonyl -N-eye1ohexy1-benzamide (367) 4- (N,N-Dipropylaminosulfonyl -N-cyclopentyl-benzamide (353) 4- (N,N-Dipropylaminosulfonyl -N-pentyl-benzamide (355) 4- (N,N-Dipropylaminosulfonyl -N-3 -methylbutyl-benzamide (355) 4- (N,N-Dipropylaminosulfonyl -N-3 -phenylpropyl-benzamide (403) 4- (N,N-Dipropylaminosulfonyl -N-4- tert .butylcyclohexyl-benzamide (423) 4- (N,N-Dipropylaminosulfonyl -N-4-phenylbutyl-benzamide (417) 4- (N,N-Dipropylaminosulfonyl -N-1-aminopropylpyrrolidine (396) 4- (N,N-Dipropylaminosulfonyl -N-3-methylcyclohexyl-benzamide (381) 4- (N,N-Dipropylaminosulfonyl -N-1-benzyl-4-aminopoperidine (458) 4- (N,N-Dipropylaminosulfonyl -N-eyelopropylmethy1-benzamide (339) 4- (N,N-Dipropylaminosulfonyl -N-buty1-benzamide (341)
EXAMPLE 2
4- (N,N-dipropylaminosulfonyl) -N-4-methoxybenzyl- benzamide
A mixture of a 75 mM solution of 4-methoxybenzylamine in chloroform (0.5 ml), a 75 mM solution of N- (dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride in chloroform (0.5 ml) and a 50 mM solution of 4- (N, N-dipropylaminosulfonyl) -benzoic acid in chloroform (0.5 ml) was stirred at room temperature for 17 hours. Methanol (0.5 ml) was added with stirring and the solution applied to a methanol-washed 500 mg SCX solid phase extraction (SPE) cartridge. The cartridge was washed with methanol (4 ml) and the combined eluates vacuum evaporated to give the required product. (TS-MS: m/z 405, [M+H]+) .
EXAMPLE 3
4- (N,N-dibutylaminosulfonyl) -N-4-methoxybenzyl-benzamide
A mixture of a 200 mM solution of dibutylamine in acetonitrile (0.5 ml) and a 25 mM solution of 4-chlorosulfonylbenzoic acid in acetonitrile (1 ml) was stirred at room temperature for 18 hours. Methanol (1 ml) was then added with stirring and the solution applied to a methanol-washed 500 mg SCX SPE cartridge. The cartridge was washed with methanol (4 ml) and the combined eluates vacuum evaporated. The residue was dissolved in dichloromethane (1 ml) and a 75 mM solution of 4-methoxybenzylamine in chloroform (0.5 ml) and a 75 mM solution of N- (dimethylaminopropyl) -N' - ethylcarbodiimide hydrochloride in chloroform (0.5 ml) added. This mixture was stirred at room temperature for 17 hours. Methanol (0.5 ml) was added with stirring and the solution applied to a methanol-washed 500 mg SCX SPE cartridge. The cartridge was washed with methanol (4 ml) and the combined eluates vacuum evaporated to give the required product. (TS-MS: m/z 433, [M+H]+)
The following compounds were prepared similarly.
Thermospray Mass
Spectrum values
4- (N-pentylaminosulfonyl) -N-4-methoxybenzyl-benzamide (391) 4- [N- (3-methylcyclohexyl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (417)
4- [ (N-butyl-N-propyl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (419)
4- [N- (3 , 5-dimethylpiperidin-l-yl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (417 )
4- [ (N-diisobutyl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (433 )
4- [N- (3-methylpiperidin-l-yl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (403 ) 4-[ (N-methylbutyl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (405)
4- [ (4-methylpiperidin-l-yl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (403 )
4- [ (3 , 3-dimethylpiperidin-l-yl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (41 )
4- [ (N-cyclopropyl-N-propylmethyl) aminosulfonyl] -N-4-methoxybenzyl-benzamide (41 )
EXAMPLE 4
3 - (N, N-dipropylaminosulf onyl ) -N-3 , 4 -dimethoxyphenethyl - benzamide A mixture of a 200 mM solution of dipropylamine in acetonitrile (0.5 ml) and a 25 mM solution of 3-chlorosulfonylbenzoic acid in acetonitrile (1 ml) was stirred at room temperature for 18 hours. Methanol (1 ml) was then added with stirring and the solution applied to a methanol-washed 500 mg SCX SPE cartridge. The cartridge was washed with methanol (4 ml) and the combined eluates vacuum evaporated. The residue was dissolved in dichloromethane (1 ml) and a 75 mM solution of 3 , 4-dimethoxyphenethylamine in chloroform (0.5 ml) and a 75 mM solution of N- (dimethylaminopropyl) -N' - ethylcarbodiimide hydrochloride in chloroform (0.5 ml) added. This mixture was stirred at room temperature for 17 hours. Methanol (0.5 ml) was added with stirring and the solution applied to a methanol-washed 500 mg SCX SPE cartridge. The cartridge was washed with methanol (4 ml) and the combined eluates vacuum evaporated to give the required product. (TS-MS: m/z 449, [M+H]+)
EXAMPLE 5
(1) 4- [ (N,N-di-n-propylamino) sulfonyl] -benzoic acid
To a stirred solution of di-n-propylamine (3.03 g, 0.03 mole) in dry tetrahydrofuran (20 ml) at 0° C. (ice/salt bath), was added 4-chlorosulfonylbenzoic acid (2.2 g, 0.01 mole). Stirring was continued for 1 hour.
Ice water was added cautiously and the reaction made acid with 2NHC1. The 4- [ (N, N-di-n- propylamino) sulfonyl] -benzoic acid was collected by filtration as a white solid which was dried in vacuo at
40° C.
Similarly prepared were:
3- [ (N,N-di-n-propylamino) sulfonyl] -benzoic acid
4- [ (N-phenyl-N-n-propylamino) sulfonyl] -benzoic acid
4- [ (N-phenyl-N-n-allylamino) sulfonyl] -benzoic acid
3- [N- (3 , 3-dimethylpiperidin-l-yl) sulfonyl] -benzoic acid 4- [N- (3 , 3-dimethylpiperidin-l-yl) sulfonyl] -benzoic acid 4- [ (N-phenyl-N-n-butylamino) sulfonyl] -benzoic acid 3- [ (N-phenyl-N-n-propylamino) sulfonyl] -benzoic acid 3- [N- (3-ethylpiperidin-l-yl) sulfonyl] -benzoic acid 3- [ (N-phenyl-N-methyl) sulfonyl] -benzoic acid 4- [N- (3-methylpiperidin-1-yl) sulfonyl] -benzoic acid
(2) 4-[ (N-di-n-propylamino) sulfonyl] -N-4-methoxybenzyl- benzamide To a solution of 4- [ (N, N-di-n-propylamino) sulfonyl] - benzoic acid (2.85 g, 0.01 mole) in dry dichloromethane (ml) at 0° C. was added oxalyl chloride (2.54 g, 0.02 mole) and dimethylformamide (4 drops) . The reaction mixture was stirred for 2 hours. The reaction was evaporated to dryness in vacuo . The resulting acid chloride was added to a stirred solution of p-methoxybenzylamine (1.51 g, 0.011 mole) and triethylamine (1.11 g, 0.011 mole) in dry tetrahydrofuran (25 ml) at 0-5° C. After stirring for 4 hours the reaction was poured into ice water and extracted with ethyl acetate. The solvent was washed with brine, dried and evaporated to dryness in vacuo . Chromatography on flash silica using 10% ethyl acetate/dichloromethane gave 4-{ (N, N-di-n- propylamino) sulfonyl] -N-4-methoxybenzyl-benzamide as a white solid. M.p. 132-134° C.
Similarly prepared were:
3- [ (N, N-di-n-propylamino) sulfonyl] -N-4-methoxybenzyl- benzamide. M.p. 132-134° C.
4- [ (N-phenyl-N-n-propylamino) sulfonyl] -N-4- methoxybenzyl-benzamide. M.p. 112-114° C. 4- [ (N-phenyl-N-n-butylamino) sulfonyl] -N-n-hexyl- benzamide. M.p. 84-86° C. 4- [ (N-phenyl-N-n-allylamino) sulfonyl] -N-n-hexyl- benzamide. M.p. 90-92° C.
4- [ (N-phenyl-N-n-propylamino) sulfonyl] -N-n-hexyl- benzamide. M.p. 92-94° C. 3- [N- (3 , 3-dimethylpiperidin-l-yl) sulfonyl] -N-4- fluorobenzyl-benzamide . M.p. 125° C.
4- [N- (3 , 3-dimethylpiperidin-l-yl) sulfonyl] -N-4- fluorobenzyl-benzamide . M.p. 138-140° C.
3- [ (N, N-di-n-propylamino) sulfonyl] -N-4-fluorobenzyl- benzamide. M.p. 84-86° C.
N-methyl-3- [N- (3 , 3-dimethylpiperidin-l-yl) sulfonyl] -N-4- fluorobenzyl-benzamide . M.p. <50° C.
N-benzyl-3- [N- (3 , 3-dimethylpiperidin-l-yl) sulfonyl] -N-4- fluorobenzyl-benzamide . M.p. 112° C. 4- [ (N-phenyl-N-n-butylamino) sulfonyl] -N-4-fluorobenzyl- benzamide . M.p. 128-130° C.
3- [ (N-phenyl-N-n-propylamino) sulfonyl] -N-4-fluorobenzyl- benzamide . M.p. 99° C.
4-[ (3, 3-dimethylpiperidin-l-yl) sulfonyl] -N- ( 2 - { [ (4- fluorophenyl) methyl] amino} ethyl) benzamide . Maleate.
M.p. 132-134° C.
3- [Ν- (3-ethylpiperidin-l-yl) sulfonyl] -Ν-4-fluorobenzyl-
benzamide. 405(M+H)+
N- [2- (dimethylamino) ethyl] -3- [ (3 , 3-dimethylpiperidin-l- yl) sulfonyl] -N-4-fluorobenzyl-benzamide maleate. M.p.
126° C. N- [2- (dimethylamino) ethyl] -3- [ (3 , 3-dimethylpiperidin-l- yl) sulfonyl] -N-cyclohexylmethyl-benzamide . M.p. 122° C. N- [2- (dimethylamino) ethyl] -4- [ (Ν-phenyl-Ν-n- propylamino) sulfonyl] -N-cyclohexylmethyl-benzamide maleate. M.p. 140-142° C.
N- [2- (pyrrolidino) ethyl] -3- [ (3 , 3-dimethylpiperidin-l- yl) sulfonyl] -N-isoamyl-benzamide hydrochloride . M.p. 179° C. N- [2- (pyrrolidino) ethyl] -4- [ (3-ethylpiperidin-l- yl) sulfonyl] -N-isoamyl-benzamide malea. M.p. 166- 168° C.
N- [3- (pyrrolidino) propyl] -3- [ (3 , 3-dimethylpiperidin-l- yl) sulfonyl] -N-isoamyl-benzamide hydrochloride. M.p. 155° C. N- [3- (pyrrolidino) propyl] -3- [ (3 , 3-dimethylpiperidin-l- yl) sulfonyl] -N-cyclohexylmethyl-benzamide . M.p. 124° C. N- [ 2- (N-methyl-pyrrolidin-2 -yl ) ethyl ] -3 - [ (3,3- dimethylpiperidin-1-yl) sulfonyl] -N-isoamyl-benzamide maleate. M.p. 115-117° C. N- [2- ( iperidin-1-yl) ethyl] -3- [ (3-methylpiperidin-l- yl) sulfonyl] -N- (2-4-methoxyphenethyl) -benzamide . M.p. 210° C.
N- [2- (piperidin-1-yl) ethyl] -3- [ (3-methylpiperidin-l- yl) sulfonyl] -N- (2-4-methoxyphenethyl) -benzamide hydrochloride. M.p. 205° C. The following Examples illustrate typical formulations containing a compound of the invention.
EXAMPLE 6
Tablets each containing 10 mg of active ingredient are made up as follows :
Active ingredient 10 mg
Starch 160 mg
Microcrystalline cellulose 100 mg
Polyvinylpyrrolidone (as 10% solution in water) 13 mg Sodium carboxymethyl starch 14 mg
Magnesium stearate 3 mg
Total 300 mg
The active ingredient, starch and cellulose are mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders and passed through a sieve. The granules so produced are dried and re-passed through a sieve. The sodium carboxymethyl starch and magnesium stearate are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 300 mg.
EXAMPLE 7
Capsules each containing 20 mg of active ingredient are made as follows:
Active ingredient 20 mg Dried starch 178 mg
Magnesium stearate 2 mg
Total 200 mg
The active ingredient, starch and magnesium stearate are passed through a sieve and filled into hard gelatine capsules in 200 mg quantities.
EXAMPLE 8
Capsules each containing 20 mg of medicament are made as follows : Active ingredient 20 mg Lactose 171 mg
Sodium lauryl sulphate 2 mg Sodium starch glycollate 6 mg Magnesium stearate 1 mg
200 mg
The active ingredient, lactose, sodium lauryl sulphate and sodium starch glycollate are mixed thoroughly. The blend is mixed with the magnesium stearate and filled into hard gelatine capsules in 200 mg quantities.
EXAMPLE 9
Tablets each containing 20 mg and medicaments are made as follows:
Active ingredient 20 mg
Lactose 103 mg
Microcrystalline cellulose 150 mg
Hydroxypropylmethylcellulose 15 mg
Sodium starch glycollate 9 mg Magnesium stearate 3 mg 3 00 mg
The active ingredient, lactose, microcrystalline cellulose, sodium starch glycollate and hydroxypropylmethylcellulose are passed through a sieve and blended together. Water is added to the blended powders to form a damp mass . The damp mass is passed through a coarse screen, dried, then re-screened. The dried granules are mixed with the magnesium stearate and compressed into tablets of 300 mg weight.

Claims

1. A compound of the formula
Figure imgf000028_0001
R3
(I)
in which the aminosulfonyl group is attached at the 3- or 4-position, and in which
R! is hydrogen, C^-ζ alkyl, C3_χo cycloalkyl, C3_ιo cycloalkyl-Cχ_4 alkyl or optionally substituted
phenyl-Cχ_4 alkyl,
R2 is Cχ_g alkyl, C3_IQ cycloalkyl, C3_ιg cycloalkyl-Cχ_4 alkyl, optionally substituted
phenyl-C!_4 alkyl or -(CH2)2NR5R6 where R5 and R6 are each hydrogen or Cχ_g alkyl, and R3 and R"4 are each Cχ_g alkyl, C3_IQ cycloalkyl,
C3_ o cycloalkyl-C _4 alkyl, C3_g alkenyl,
optionally substituted phenyl or optionally substituted phenyl-Cχ_4 alkyl,
or R1 and R2 r or R3 and R4 ^ or R5 and R6 , together
with the nitrogen atom to which they are attached, form a carbocyclic group containing 4 to 7 carbon atoms optionally substituted with one to three methyl or ethyl groups and optionally containing an oxygen atom or a further nitrogen atom, said carbocyclic group being optionally fused to an optionally substituted phenyl group;
or a salt thereof
2. A compound according to Claim 1 in which R1, R , R^
and R4 are each Cχ_g alkyl, C3_IQ cycloalkyl, C3_χo cycloalkyl-C]__4 alkyl or optionally substituted
phenyl-C^-4 alkyl, and R! can in addition be
hydrogen, or R! and R , or R^ and R*4 together with the nitrogen atom to which they are attached, form a carbocyclic group.
3. A compound according to Claim 2 in which R^, R2 , R^
and R are each Cχ_g alkyl, C3_]_Q cycloalkyl, C3_χo cycloalkyl-C _4 alkyl or optionally substituted
phenyl-C]__4 alkyl, and R1 can in addition be
hydrogen .
4. A compound according to Claim 3 in which R! is
hydrogen, R2 is optionally substituted phenyl-C╬╣_4
alkyl and R3 and R4 are C╬╣_ alkyl.
5. A compound according to Claim 1 in which R2 is
-(CH2)2NR5R6.
6. A compound according to Claim 1 or 5 in which R3 or
R4 is C3_g alkyl or when R3 and R4 are taken
together with the nitrogen atom they form a piperidine ring which is substituted at the 3- and/or 5-positions with one or two methyl or ethyl substituents.
7. A pharmaceutical formulation comprising a compound according to any of Claims 1 to 6 or a pharmaceutically acceptable salt thereof, together with a diluent or carrier therefor.
8. A compound according to any of Claims 1 to 6 , for use as a pharmaceutical .
9. Use of a compound according to any of Claims 1 to 6, in the manufacture of a medicament for treating a disease of the central nervous system.
10. A process for producing a compound according to
Claim 1, which comprises reacting a compound of the formula
Figure imgf000031_0001
(II)
where X is a leaving group, with an amine of the
formula HNR^-R2.
PCT/GB1999/000099 1998-01-14 1999-01-13 Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels WO1999036398A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU21728/99A AU2172899A (en) 1998-01-14 1999-01-13 Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels
EP99901722A EP1047670A1 (en) 1998-01-14 1999-01-13 Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels
JP2000540115A JP2002509135A (en) 1998-01-14 1999-01-13 Aminosulfonylbenzamide derivatives as modulators of neuronal calcium channel activity
CA002317536A CA2317536A1 (en) 1998-01-14 1999-01-13 Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800750.3A GB9800750D0 (en) 1998-01-14 1998-01-14 Pharmaceutical compound
GB9800750.3 1998-01-14

Publications (1)

Publication Number Publication Date
WO1999036398A1 true WO1999036398A1 (en) 1999-07-22

Family

ID=10825269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000099 WO1999036398A1 (en) 1998-01-14 1999-01-13 Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels

Country Status (6)

Country Link
EP (1) EP1047670A1 (en)
JP (1) JP2002509135A (en)
AU (1) AU2172899A (en)
CA (1) CA2317536A1 (en)
GB (1) GB9800750D0 (en)
WO (1) WO1999036398A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027068A2 (en) * 2001-09-24 2003-04-03 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
JP2005522437A (en) * 2002-02-06 2005-07-28 シェーリング　コーポレイション γ-secretase inhibitor
US6936638B2 (en) 2002-12-20 2005-08-30 Migenix Corp. Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
EP1602368A2 (en) * 2000-07-28 2005-12-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Cdc25 phosphatase inhibitors
WO2008118758A1 (en) * 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
WO2011141728A1 (en) * 2010-05-10 2011-11-17 Convergence Pharmaceuticals Limited Spirocyclic derivatives with affinity for calcium channels
WO2011141729A1 (en) * 2010-05-10 2011-11-17 Convergence Pharmaceuticals Limited Novel compounds
US9758477B2 (en) 2011-07-01 2017-09-12 Drexel University Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
WO2021007474A1 (en) * 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605174B2 (en) * 2005-06-09 2009-10-20 Vertex Pharmaceuticals Incorporated Indane derivatives as modulators of ion channels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591754A (en) * 1992-09-22 1997-01-07 Hoechst Aktiengesellschaft Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591754A (en) * 1992-09-22 1997-01-07 Hoechst Aktiengesellschaft Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.H ANDREWS, ET AL.: "Experimental chemotherapy of typhus. Antirickettsial action of p-sulphamylbenzamidine and related compounds", PROCEEDINGS OF THE ROYAL SOCIETY OF LONDON, SERIES B - BIOLOGICAL SCIENCES, vol. 133, 1946, London, GB, pages 20 - 60, XP002100404 *
K. YONEYAMA, ET AL.: "Phytotoxic activity of N-benzylbenzenesulphonamides", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 48, no. 2, February 1984 (1984-02-01), New York, US, pages 491 - 498, XP002100406 *
P. BEAK, ET AL.: "The tertiary amide as an effective director of ortho lithiation", JOURNAL OF ORGANIC CHEMISTRY, vol. 47, no. 1, 1 January 1982 (1982-01-01), Washington, DC, US, pages 34 - 46, XP002100405 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1602368A3 (en) * 2000-07-28 2009-09-02 Ipsen Pharma Cdc25 phosphatase inhibitors
EP1602368A2 (en) * 2000-07-28 2005-12-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Cdc25 phosphatase inhibitors
WO2003027068A3 (en) * 2001-09-24 2004-04-08 Elan Pharm Inc Substituted amines for the treatment of neurological disorders
WO2003027068A2 (en) * 2001-09-24 2003-04-03 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
JP2005522437A (en) * 2002-02-06 2005-07-28 シェーリング　コーポレイション γ-secretase inhibitor
JP4758609B2 (en) * 2002-02-06 2011-08-31 シェーリング コーポレイション γ-secretase inhibitor
US6936638B2 (en) 2002-12-20 2005-08-30 Migenix Corp. Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
WO2008118758A1 (en) * 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
WO2011141728A1 (en) * 2010-05-10 2011-11-17 Convergence Pharmaceuticals Limited Spirocyclic derivatives with affinity for calcium channels
WO2011141729A1 (en) * 2010-05-10 2011-11-17 Convergence Pharmaceuticals Limited Novel compounds
US9758477B2 (en) 2011-07-01 2017-09-12 Drexel University Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2021007474A1 (en) * 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications

Also Published As

Publication number Publication date
CA2317536A1 (en) 1999-07-22
EP1047670A1 (en) 2000-11-02
JP2002509135A (en) 2002-03-26
GB9800750D0 (en) 1998-03-11
AU2172899A (en) 1999-08-02

Similar Documents

Publication Publication Date Title
KR0142417B1 (en) Tertiary alkyl functionalized piperazine derivatives
US6617325B1 (en) Biphenyl derivatives, production thereof and uses as medicines
US7365077B2 (en) Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
EP0158775B1 (en) Substituted sulfonamidobenzamides, antiarrythmic agents and compositions thereof
CA1235122A (en) Substituted trans-1,2-diaminocyclohexyl amide compounds
WO1996041802A1 (en) Novel heteroaromatic piperazines for use as drugs
HU221315B1 (en) Alkyl-substituted piperazine derivatives, pharmaceutical compositions containing them, and process for producing them
NO338104B1 (en) Tetrahydroisoquinoline-sulfonamide derivatives, pharmaceutical compositions containing them and their use as therapeutic agents
EP1047670A1 (en) Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels
EP0290377B1 (en) Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents
WO1995029152A1 (en) Benzamide derivatives as vasopressin antagonists
KR20010070997A (en) Biphenyl derivatives
EP0324791B1 (en) Aryl-n-aminoalkyl-4-(sulfonamido)benzamides, antiarrhytmic agents and compositions thereof
CA2244940A1 (en) Novel piperidines derived from 1-/(piperazin-1-yl)aryl(oxy/amino)carbonyl/-4-aryl-piperidine as selective 5-ht1db receptor antagonists
GB2352240A (en) Novel sulphonamides useful in treating CNS disorders
HUT73526A (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
FR2740134A1 (en) CYCLIC AMINE DERIVATIVES OF ARYL-PIPERAZINES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20080076760A1 (en) 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition
WO1998031669A1 (en) Novel arylpiperazine derived from piperidine as antidepressant medicines
US5486518A (en) 4-indolylpiperazinyl derivatives
KR20040007672A (en) Novel Phenylalkyl Diamine and Amide Analogs
AU3964393A (en) Novel amidoalkyl- and imidoalkyl-piperazines
KR20030024919A (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
CA2173693A1 (en) 4-indolylpiperazinyl derivatives
CA1133495A (en) Cis and trans-3-aryloxy-4- hydroxypyrrolidines and derivatives thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999901722

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2317536

Country of ref document: CA

Ref country code: CA

Ref document number: 2317536

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09582601

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999901722

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999901722

Country of ref document: EP